Welcome to our dedicated page for Astrotech Corporation (DE) news (Ticker: ASTC), a resource for investors and traders seeking the latest updates and insights on Astrotech Corporation (DE) stock.
Astrotech Corporation (DE) Common Stock (symbol: ASTC) is a pioneering science and technology development company. The firm is renowned for its commitment to inventing, acquiring, and commercializing cutting-edge technological innovations sourced from internal research, universities, laboratories, and research institutions. Astrotech's diverse operations span several key sectors, including airport security, military applications, breath analysis, and agriculture.
One of Astrotech's flagship ventures is 1st Detect, which specializes in the development, manufacturing, and sale of advanced chemical analyzers. These tools are instrumental in enhancing security measures at airports and military installations, as well as in medical diagnostics through breath analysis. The company's TRACER 1000™, a mass spectrometry-based trace analyzer, has recently expanded its detection library to include narcotics such as fentanyl, heroin, and cocaine, highlighting its significant role in combating drug trafficking and ensuring public safety.
Another innovative branch of the company is AgLAB, which focuses on developing mass spectrometers for the agriculture market. The AgLAB's Maximum Value Process™ has demonstrated a remarkable 32% average increase in revenue, underscoring its efficacy in optimizing agricultural outputs and enhancing profitability for farmers and agribusinesses.
Astrotech continues to innovate with its latest venture, Pro-Control, Inc., a wholly owned subsidiary formed to leverage the ATi Mass Spectrometer Technology for chemical manufacturing process control applications. The introduction of the Pro-Control Maximum Value Process™ (Pro-Control MVP™) and the Pro-Control-1000™ mass spectrometer reflects Astrotech's commitment to delivering value through improved yield, potency, purity, and weight measurements in chemical manufacturing processes.
With a history of over 110 years, Astrotech has built a solid reputation based on its ability to provide reliable equipment and solutions that drive business efficiencies. The company is known for its global service and superior parts availability, ensuring long-term operational success for its clients. By visiting Telsmith, customers can learn more about how Astrotech's innovative products and services can enhance the performance of their operations.
Astrotech's commitment to innovation and excellence is further evidenced by its recent listing as an approved United States Government Vendor on the General Services Administration (GSA) schedule, opening new avenues for government contracts and partnerships.
For the latest updates and detailed information about Astrotech's performance, ongoing projects, and recent achievements, investors and stakeholders are encouraged to stay informed through the latest news releases and company announcements.
Astrotech Corporation (Nasdaq: ASTC) has appointed Thomas B. Pickens III as Chief Technology Officer, complementing his role as CEO. This dual role highlights Pickens' expertise in advancing the company’s proprietary Astrotech Mass Spectrometer Technology (AMS Technology). Since 2017, he has played a crucial role in developing products such as the BreathTest-1000 for COVID-19 detection. Additionally, he is leading initiatives in essential oils distillation using AMS Technology. The company anticipates that this leadership change will enhance commercial value, although it faces uncertainties regarding FDA approvals for its products.
Astrotech Corporation (Nasdaq: ASTC) announced an expansion of its Board of Directors from four to five members, appointing Bob McFarland as a new director. McFarland brings extensive executive management experience, particularly in information technology, having served at the Department of Veterans Affairs as Chief Information Officer. His experience includes significant roles at Dell, where he managed government relations. The Board welcomes McFarland's expertise, particularly as Astrotech develops its mass-spectrometry technologies, including the BreathTest-1000, and navigates FDA approval processes.
Astrotech Corporation (Nasdaq: ASTC) announced the adoption of a limited-duration stockholder rights plan effective immediately, aimed at protecting the interests of all stockholders. This plan responds to significant accumulations of common stock, ensuring fair treatment and reducing the risk of hostile takeovers. The plan is set to last for 364 days, expiring on December 20, 2023, and is triggered if a person or group acquires 15% or more of the shares. The rights will be distributed to stockholders of record by January 5, 2023.
Astrotech Corporation (Nasdaq: ASTC) announced on December 21, 2022, that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This achievement enables the company to maintain its listing on the Nasdaq Capital Market, as confirmed by Nasdaq. Astrotech focuses on mass spectrometry technology through its subsidiaries, including 1st Detect for security detection, AgLAB for agricultural chemical analysis, and BreathTech for early lung disease detection.
Astrotech Corporation (Nasdaq: ASTC) announced a 1-for-30 reverse stock split effective December 5, 2022, to comply with Nasdaq's $1.00 minimum bid price requirement. This split will reduce the number of shares and increase the per-share price, allowing ASTC to maintain its listing. Stockholders approved the reverse split at the annual meeting on November 15, 2022, and no fractional shares will be issued; instead, cash payments will be provided for fractions. Astrotech specializes in mass spectrometry and operates subsidiaries focused on security and agriculture.
Astrotech Corporation announced a breakthrough with its BreathTest-1000 device, capable of distinguishing between infected and healthy breath samples, indicating potential for early lung disease detection. The technology targets COVID-19 and other respiratory diseases, aiming for on-site results in various settings like hospitals and schools. Collaborations with Cleveland Clinic and Mountain View Clinical Research are in place to enhance the data collection process. While progress is noted, risks persist, particularly regarding regulatory approvals and market acceptance.
Astrotech Corporation (Nasdaq: ASTC) subsidiary, AgLAB, Inc., has launched the AgLAB-1000-D2™ and Maximum Value Processing™ (D2-MVP) control system, aimed at enhancing cannabis and hemp processing.
The D2-MVP system can improve yields, potencies, and revenues by up to 45% compared to traditional methods, with results produced in under a minute. The product is tailored for chemical distillation and is currently adapted for hemp CBD and cannabis THC oils. However, development risks are acknowledged, including regulatory approvals and market acceptance.
Astrotech Corporation (NASDAQ: ASTC) reported its financial results for Q1 of fiscal 2023, ending September 30, 2022, with revenues totaling $38,000, attributed to maintenance services and consumables for TRACER 1000. The company has $48.9 million in cash and liquid investments to support R&D and growth. Significant developments include the production run of the AgLAB-1000-D2, showing promise in increasing processing yields for hemp and cannabis distillers, and progress in BreathTest-1000’s development. A $1 million share repurchase program was also authorized.
Astrotech Corporation (NASDAQ: ASTC) reported strong financial performance for the fiscal year ending June 30, 2022, with a notable revenue increase of 160%, reaching $869K, driven by sales of the TRACER 1000 explosive trace detector. The company maintains a robust balance sheet with $52.6 million in cash and liquid investments. Gross margins improved to 22%, doubling from the previous year. Key advancements include securing a significant purchase order for TRACER 1000 systems and leadership appointments in its subsidiaries to drive innovation in various product developments.
Astrotech Corporation (NASDAQ: ASTC) has announced its fiscal year 2022 annual meeting of stockholders, scheduled for November 15, 2022, at 9:00 a.m. Central Time, in Austin, Texas. Proxy materials will be sent to stockholders in September 2022. Due to a change in the meeting date, stockholders must submit proposals by September 3, 2022, for nominations or business proposals outside of Rule 14a-8, and by September 12, 2022, for proposals under Rule 14a-8. Detailed information will be provided in the forthcoming proxy statement.
FAQ
What is the current stock price of Astrotech Corporation (DE) (ASTC)?
What is the market cap of Astrotech Corporation (DE) (ASTC)?
What does Astrotech Corporation do?
What is the TRACER 1000™?
What are some recent developments at Astrotech?
What is AgLAB's Maximum Value Process™?
How does Astrotech contribute to airport security?
What industries does Astrotech serve?
How long has Astrotech been in business?
Is Astrotech a government-approved vendor?
What is the Pro-Control Maximum Value Process™?
How can I learn more about Astrotech's products and services?
